^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TQB2930

    i
    Other names: TQB2930, TQB-2930
    Associations

    News

    Trials
    Company:
    Sino Biopharm
    Drug class:
    HER2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2d
    Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=178, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression • HER-2 underexpression
    |
    TQB2102 • TQB2930
    2ms
    Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=178, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression • HER-2 underexpression
    |
    TQB2102 • TQB2930
    11ms
    TQB2930-III-01: TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=416, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Herceptin (trastuzumab) • capecitabine • eribulin mesylate • TQB2930
    11ms
    TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=416, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
    New P3 trial
    |
    Herceptin (trastuzumab) • capecitabine • eribulin mesylate • TQB2930
    2years
    A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer (clinicaltrials.gov)
    P1/2, N=154, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=89 --> 154 | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    gemcitabine • paclitaxel • capecitabine • fulvestrant • eribulin mesylate • vinorelbine tartrate • Saitanxin (culmerciclib) • TQB2930
    over2years
    A Study of TQB2930 for Injection Monotherapy or Combination Chemotherapy in Patients With Recurrent/Metastatic Breast Cancer (clinicaltrials.gov)
    P1/2, N=89, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1/2 trial • Metastases
    |
    docetaxel • TQB2930
    4years
    Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers (clinicaltrials.gov)
    P1, N=60, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    TQB2930